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Abstract: Sono-crystallisation has been used to enhance crystalline product quality particularly in
terms of purity, particle size and size distribution. In this work, the effect of impurities and ultrasound
on crystallisation processes (nucleation temperature, yield) and crystal properties (crystal size
distribution determined by Focused Beam Reflectance Measurement (FBRM), crystal habit, filtration
rate and impurity content in the crystal product by Liquid Chromatography-Mass Spectroscopy
(LC-MS)) were investigated in bulk suspension crystallisation experiments with and without the
use of ultrasound. The results demonstrate that ultrasonic intervention has a significant effect on
both crystallisation and product crystal properties. It increases the nucleation rate resulting in
smaller particles and a narrower Particle Size Distribution (PSD), the yield has been shown to be
increase as has the product purity. The effect of ultrasound is to reduce the level acetanilide impurity
incorporated during growth from a 2 mol% solution of the selected impurity from 0.85 mol% to
0.35 mol% and likewise ultrasound reduces the uptake of metacetamol from 1.88 mol% to 1.52 mol%.
Keywords: suspension crystallisation; impurities; crystal size distribution; filtration rate; optical
microscopy; image analysis; crystal morphology; purification; HPLC; ultrasound intensity
1. Introduction
Crystallisation is the principal purification technique in the pharmaceutical, fine chemical, paint,
pigments and agrochemical sector. It allows the desired product to be obtained in a pure state leaving
unwanted or hazardous impurities in solution where they can be removed effectively by filtration
and washing. During crystallisation, molecules of the product assemble together to form crystals
with a regular 3D packing arrangement known as a crystal lattice. Purification occurs by molecular
recognition at the solution-lattice interface. The mismatch between some impurity molecules and the
crystal lattice is so significant that the impurity molecule cannot be incorporated in the lattice and is
rejected. However, if the molecular mismatch is small enough, the impurity molecule can become
incorporated into the crystal lattice. If the portion of the impurity molecule projecting out from the
crystal surface is different from the adjacent molecules in the surface layer of the crystal this is likely
to disrupt and retard subsequent growth at that growth site and adjacent sites on that crystal face.
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Increasing the crystallisation driving force, i.e., increasing supersaturation level, reduces selectivity
allowing easier incorporation of the impurity into the crystal lattice and subsequent overgrowth. In one
of the author’s industrial experience, typical feed streams to industrial crystallisation contain several
mole% of impurities so interactions between impurity molecules and the growing crystal surface are
very frequent and can have undesirable consequences. Impurity poisoning of growing crystal faces
increases processing time and slows the approach to equilibrium. In some instances, a significant
amount of product has to be left in solution and lost in the waste stream in order for the process to be
run with a plausible batch duration. Sometimes the product is so impure that it has to be re-crystallised
to meet the required specification.
Most impurities that are readily incorporated into the growing crystal lattice and act as crystal
growth inhibitors are close analogues of the active pharmaceutical ingredient and are produced
inadvertently as by-products or degradants during the synthetic process. As well as retarding crystal
growth they also modify crystal habit. As a consequence, other attributes of the isolated crystals such
as bulk density and powder flow are modified and can influence both the subsequent formulation
process and drug product performance. Several routes have been identified [1] by which impurities
become entrapped in final crystalline product: (i) Deposition on crystal surfaces due to the incomplete
removal of impure mother liquor during filtration and washing; (ii) incorporation within the crystal
lattice by molecular recognition/substitution or (iii) entrapment of multiple impurity molecules within
inclusions or between individual crystallites in agglomerates. The impact of specific impurities on
crystallisation processes depends on; the structure of the impurity, its concentration, the crystallisation
solvent, the supersaturation and the temperature of the crystallising solution. The presence of
impurities during the crystallisation process can significantly modify the kinetics of nucleation,
the growth rate of specific crystal faces, crystal morphology (habit) and the polymorphic phase
crystallized. These undesired effects can cause costly delays during the research and development
process within the pharmaceutical industry. There are many case studies of impurity effects reported in
the crystallisation literature [2–5]. The effect of increasing amounts of the impurity p-acetoxyacetanilide
on paracetamol nucleation is to increase the metastable zone width and lengthen the induction
time [3,6,7]. It has been reported that this due to its ability to disrupt the formation and growth of the
critical nucleus [3,8]. Impurities have been reported both to suppress and occasionally to accelerate
crystal growth processes [9]. N-phosphonomethyl phosphoric acid (PMG) crystallisation is reported
to be affected by the impurities, iminobismethylene phosphonic acid and amino methyl phosphoric
acid by selective absorption onto the (100) face inhibiting the growth of this face; while the impurity
N-phosphonomethyl iminodiacetic acid (PIDA) does not change crystal habit noticeably [10]. Also,
an impurity has been reported to affect the solution-mediated phase transformation of the metastable
A form to the stable B form of an active pharmaceutical ingredient [11]. The presence of impurities
is widely reported to influence crystal growth and crystal morphology [9,12–15]. This is the case for
amino acids on the habit of glycine crystals [16], or urea crystallisation in the presence of biuret [15].
The change of crystal habit is due to a difference in the extent of adsorption and magnitude of binding
energies on different crystal faces [16]. For this reason, identification, quantification and reduction of
impurities in the early stages of synthetic process development can avoid problems in crystallisation
development, enhance product performance and reduce development time [17].
Ultrasound (US) has been used in the chemical and food industries to enhance crystalline product
quality in terms of particle size, size distribution and impurity and is termed sono-crystallisation.
Ultrasound has been widely reported to influence the primary nucleation process accelerating
nucleation kinetics, this is typically expressed in terms of reducing the induction time and
MSZW [18–33]. Ultrasound can also increase the rate of secondary nucleation, this is manifested
as a reduction on the product crystal size distribution [20,22,24,31,32,34–43]. Ultrasound can
also influence crystal growth [20,25,26,36,40,44–46] although the effect on crystal growth is not as
dramatic as on nucleation and arises largely from enhanced mass transfer [46] and can influence
crystal morphology. Other reported outcomes of ultrasonic intervention include influencing;
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which polymorph nucleates [23,47,48], crystal structure [30], crystal properties [49] and reaction
crystallisation [45]. Several proposed mechanisms of the effect of ultrasound on crystallisation have
been published. These include the formation of local hot spots which arise from the large energy release
on the collapse of cavitation bubbles creating highly localised regions of extremely high temperature
and pressure [50,51], or due to rapid cooling which follows; shockwaves released from cavitation
bubbles [52,53], promoting mass transfer and collisions between crystals and adjacent surfaces [54].
These effects of ultrasound on crystallisation have been demonstrated on pharmaceuticals and
commodity chemicals including; lactose [35,39,42,55], alpha-dextrose monohydrate [20], glycine [48],
p-aminobenzoic acid [47], adipic acid [28], benzoic acid [31], acetylsalicylic acid [27], protein [19]
various food products [30,56,57] and in the crystallisation of inorganic materials such as potassium
sulphate [26], potassium dihydrogen phosphate [32] and calcite [34]. Ultrasound has also been utilized
in continuous crystallisation [28,58–60]. While some authors mention that ultrasound can improve
crystal purity [54]; there is very limited data on the effect of ultrasound on the purity of the final
crystalline product. This work focuses on the use of ultrasound in suspension crystallisation processes
to improve product purity, yield and crystal size distribution. The objective is to develop a bulk
suspension sonocrystallisation process at lab scale which exploits ultrasound to improve product
purity, yield and crystal habit. The research hypothesis is that through active intervention in the
molecular processes occurring at growing surfaces it may be possible to remove impurity molecules
from the surfaces and reduce the entrapment of impurities inside agglomerates formed during growth.
These measurements aim to increase understanding of how ultrasonic interventions affect product
purity both directly through influencing impurity incorporation during growth and indirectly through
influencing nucleation kinetics, crystal size distribution and agglomeration, which all influence the
purity of final products by modifying the extent to which impurities are removed during filtration
and washing.
Paracetamol (Acetaminophen) has been used as a model compound for this study because its
crystallisation behaviour is well characterised [2–5] and multiple structurally related impurities are
readily available. Three polymorphs of paracetamol have been reported [61–63] but so far only forms
I and II have been obtained as single crystals which have allowed the crystal structure to be solved.
Polymorph I (monoclinic, P21/n) is the thermodynamically stable form at room temperature, this can
be prepared as large single crystals from solutions in various solvents. Polymorph II (orthorhombic,
Pcab) is metastable at ambient conditions. Crystals of paracetamol form I exhibit three dominant
crystal habit faces; {100}, {001} and {110}. Individual paracetamol crystals exhibit different crystal
habits, for example significant changes of the growth rate and resultant morphology of paracetamol
single crystals are observed in pure [64] and impure systems [4].
2. Materials and Methodology
2.1. Materials
Paracetamol (BioXtra grade, purity ≥ 99.0%, Lot number 637515L263) was obtained from
Sigma-Aldrich (St. Louis, MO, USA). The impurities investigated were Acetanilide 99.0% Lot number
STBD0193V and Metacetamol 97.0% Lot number MKBX4643V both also obtained from Sigma-Aldrich,
all three samples were analysed on receipt to confirm the reported assay. The basis for selecting
acetanilide is that it is structurally similar to paracetamol but lacks the hydroxyl group and so while
it may be incorporated into the crystal lattice it is deficient in a hydrogen bonding opportunity.
Metacetamol was selected as a positional isomer which is also likely to be incorporated into the
crystal lattice; however, the misplaced hydroxyl group is likely to disrupt the local hydrogen bonding
arrangement. Importantly both are more soluble than paracetamol in 3-methyl-1-butanol, the selected
solvent ensuring little risk of them crystallizing independently during the experiments.
The crystallisation solvent 3-methyl-1-butanol (isoamyl alcohol) was selected because the
solubility relationship with temperature for paracetamol is appropriately steep over the chosen
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temperature range and the product crystals tend not to form agglomerates. 3-methyl-1-butanol
was obtained from Sigma-Aldrich 98%, n-heptane 99% from Alfa Aesar (Ward Hill, MA, USA) used for
filter cake washing following filtration. HPLC grade methanol and water used for the analysis were
purchased from Sigma-Aldrich.
2.2. Equipment Apparatus
2.2.1. Solubility Measurements
Gravimetric Method
In order to evaluate the effect of impurities on the crystallisation of paracetamol it was first
necessary to measure the extent to which the impurities affect the solubility of paracetamol in the
crystallisation solvent. Solubility measurements were performed by equilibration using a Stuart SI60D
Incubator (Stuart, Staffordshire, UK). Agitation of the equilibrating samples was provided by a Thermo
scientific submersible telesystem 15.20 magnetic stirrer plate (Thermo Fisher Scientific, Waltham,
MA, USA). The temperature was recorded using an Omega HH800SW temperature sensor (Omega,
Manchester, UK). Samples were taken using an Eppendorf pipette weighed on an A&D GR series
balance (A&D Instruments Limited, Manchester, UK) and evaporated to dryness in a Memmert GmbH
vacuum oven V0200 (Memmert GmbH + Co. KG, Schwabach, Germany) at 55 ◦C.
Detection of the Dissolution Temperature Method Using Crystalline-Technobis Crystallisation Systems
Solubility measurements of acetanilide and metacetamol were also conducted in a Technobis
Crystalline system, a multi-reactor crystallisation platform which has eight independent Peltier
heater-coolers able to maintain temperatures from −15 ◦C to 150 ◦C. Each 8 mL (34 × 10 mm)
crystallizer is equipped with a three-blade marine impeller with overhead stirring. Each vessel position
is equipped with a turbidity sensor and a camera allowing turbidity and images to be recorded and
synchronised with the temperature time profile.
2.2.2. Sono-Crystallisation Studies
A schematic diagram of the experimental equipment used to evaluate the effect of ultrasound on
crystal purity is shown in Figure 1. The system comprised two cell culture flasks, double side arm,
Celstir® 125 mL placed onto a submersible Telesystem 15.20 stirrer from Thermo Scientific (Waltham,
MA, USA) immersed in a XUB25 ultrasonic bath from Grant Instruments (Cambridge, UK) operating at
35 ± 3 kHz. The temperature of the water in the ultrasonic bath and hence the solutions in the Celstir®
flasks was controlled using an Immersion Compact Thermostat (ICC) from IKA (Staufen im Breisgau,
Germany) which was connected to a Hailea HC-150A chiller (GuangDong, China). Additional cooling
capacity was provided by a stainless-steel dip coil running around the base of the ultrasonic bath
and connected to a Lauder LCK1913, ECO RE 420G thermocirculator (Lauda Brinkmann, NJ, USA).
The temperature of solutions was monitored using a precise PPL-GMH-3750 thermometer and Pt100
probe (±0.03 ◦C) (GHMMesstechnik GmbH Standort Greisinger, Regenstauf, Germany). The point
of nucleation was determined by visual observation, initially a few particles were observed and the
solution gradually became cloudy. On completion of the crystallisation (~3–3.5 h after nucleation
process occurs) the product crystal size distribution was measured in situ by Focused Beam Reflectance
(FBRM) (Mettler Toledo, Greifensee, Switzerland). The product suspension was filtered using a Vac
Master 10 system (Biotage Ltd., Uppsala, Sweden) which had been modified to accommodate 50 mL
graduated cylinders which allowed the filtration rate to be measured, filtration to be halted at dry land,
and the mother liquor and individual wash liquors to be segregated for subsequent assay. The filtration
driving force was monitored and controlled using a Büchi V800 vacuum controller (Büchi UK Ltd.,
Oldham, UK).
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Figure 1. (a) Schematic diagram and (b) Annotated photograph showing the experiment setup for
suspension cooling crystallisation of paracetamol in the presence of impurities using an ultrasonic bath.
Chemical analysis of product crystals, mother liquors and wash liquors was performed using an
Agilent High Performance Liquid Chromatography 6130 dual source model (Agilent, Santa Clara, CA,
USA) provided with a thermostated autosampler, a thermostated column compartment and a single
wavelength ultraviolet (UV) detector and a 2.7 µm Poroshell 120 EC-C18 Column: 4.6 × 75 mm to
determine the crystalline product purity.
2.3. Experimental Method
2.3.1. Solubility
Gravimetric Method
Solubility measurements were performed by equilibration using a Stuart SI60D Incubator operated
over the temperature range 25 to 50 ◦C. The sample size employed to prepare saturated solutions to
determine solubility was 15 mL. The effect of impurities on solubility was determined by dissolving
a known target amount of metacetamol and/or acetanilide in the solvent prior to the addition of
paracetamol. Individual vials were prepared with specific impurity loadings and then equilibrated
with an excess of paracetamol. The vials were placed onto a Thermo scientific submersible telesystem
15.20 magnetic stirrer plate and agitated at 190 rpm. The temperature was kept within ±0.2 ◦C of the
desired temperature which was recorded with an Omega precise thermocouple. After equilibration for
24 h, the excess solid paracetamol was allowed to settle for 1 h without agitation. A 2 mL sample of the
clear saturated solution was withdrawn using an Eppendorf pipette taking great care not to disturb
the settled solids. The samples were then transferred into a labelled and weighed vial. The sample
vial containing the saturated solution was weighed immediately. This sampling process was repeated
for each equilibrated vial and the samples were placed in a fume hood and allowed to evaporate to
dryness for 24 h, after evaporation the samples, were then transferred to a vacuum oven and allowed
to dry for a further 48 h at 55 ◦C. The dry residue mass, was determined and the solubility, expressed
in mg of solute/g of solvent, was calculated with subtraction of the known amount of impurity in the
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dry samples based on the presumption that the impurity remained evenly distributed throughout the
liquid phase.
Dissolution Temperature Detection Method
A series of suspensions of known concentration of metacetamol (50–130 mg/g) and acetanilide
(80–200 mg/g) in 3-methyl-1-butanol were prepared in 8 mL vials. The vials were heated from 5 ◦C to
70 ◦C at heating rate 0.1 ◦C/min. The temperature of dissolution was determined at the point at which
all the particles were completely dissolved. By making measurements across a range of compositions
the solubility curve was determined and the solubility at specific temperatures within this range can
be interpolated.
2.3.2. Ultrasonic Intensity Measurements
The sonomechanical activity from the XUB25 ultrasonic bath was characterised by measurement
of acoustic intensity using a NH4000 PVDF needle hydrophone (Precision Acoustics Ltd., Dorset,
UK). The experimental arrangement was as shown in Figure 1 except the lid of the Celstir vessel was
replaced with a plug manufactured from PVC that allowed the needle hydrophone to be positioned
25 mm from the base of the Celstir vessel, aligned with the central axis of the same. In order to
make measurement of acoustic intensity within the Celstir vessel, the time domain waveform from
the NH4000 hydrophone was recorded with an Agilent Technologies InfinniVision X2024-A digital
oscilloscope (Agilent Technologies, South Queensferry, UK). A timing trigger for the measurement
was provided via a submersible piezoelectric transducer, sensitive at the operating frequency of the
XUB25 bath, and positioned on the top surface of the stirrer plate.
Prior to starting the measurements, the NH4000 hydrophone was wetted and soaked for 1 hour
in deionised water. As was described in Section 2.3.3, the crystallisation was undertaken using organic
solvent which is incompatible with the PVDF hydrophone tip. In order to protect the hydrophone tip
during the measurement of the acoustic intensity in the crystallisation medium, the hydrophone was
placed inside an 8 mm diameter latex rubber sheath filled with deionised water. The Celstir vessel
used for suspension crystallisation experiments was filled with an aliquot of the crystalisation solvent;
the hydrophone, complete with protective sheath, was immersed into the crystallisation medium as
shown in Figure 2. Measurements of acoustic intensity were then undertaken with the crystallisation
vessel placed inside the XUB25 bath, it was located around the defined positions on the stirrer plate at
the bottom of the ultrasonic bath—all measurements were recorded at 30 ◦C. The peak instantaneous
acoustic intensity of the recorded waveform was determined at both 50% and 100% power setting on
the XUB25 bath.
 
Figure 2. Photograph of the hydrophone arrangement within the Celstir vessel set-up for ultrasonic
intensity measurement.
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2.3.3. Sono-Crystallisation
A 150 mL suspension containing 12.65 g of paracetamol and 1% or 2% mol of metacetamol
and/or acetanilide in 115 g 3-methyl-1-butanol was prepared in cell culture flasks, Celstir® 125 mL.
The paracetamol suspension in 3-methyl-1-butanol with the presence of impurities, was immersed and
sonicated in the ultrasonic bath, XUB25, operating at 35 ± 3 kHz and was continuously stirred at a
rate of ~150 rpm using a submersible Telesystem 15.20. The solution was heated to 65 ◦C and held at
65 ◦C for 15 min to ensure complete dissolution which was verified by visual inspection before slow
cooling to 15 ◦C over 2 h. During the cooling crystallisation process, the nucleation temperature of the
solutions was recorded. At the end of the crystallisation (3 h after nucleation) and immediately prior
to isolation, the crystal size distribution was measured in situ using an FBRM to determine the mean
chord length distribution. Then the product crystals were separated from the mother liquors using
the modified VacMaster 10 system at pressure driving force of 200 mbar using a 70 mL Isolute filter
tube with a polyethylene filter with a nominal pore size of 10 µm (Biotage Ltd., Uppsala, Sweden).
The time required to collect filtrate volumes of 5 mL, 10 mL, 15 mL etc. were recorded. The filtration
was halted at “dry land” the point where the filter cake surface is first exposed above the mother
liquors. The mass of the solvent wet cake was measured. From the filtration data, the filtration rate
and filter cake resistance were obtained using Darcy’s equation [65].
dt
dV
=
µαC
∆PA2
V +
µRm
A∆P
(1)
where: t is time (s); V is volume (m3); α is cake resistance (m/kg); µ is the mother liquor viscosity
(kg/s.m); ∆P is pressure difference (Pa); C is concentration of solids (kg/m3); A is area of cake (m2);
Rm is resistance of filter medium (m−1).
In this work, filtration was carried out at constant pressure difference, ∆P = 200 mbar. Integration
Darcy’s equation gives:
t
V
=
µαC
2∆PA2
V +
µRm
A∆P
(2)
Plotting t/V versus V will allow the cake resistance α to be determined.
The ratio of the concentration of impurity in the product crystals to the concentration of impurity
relative to paracetamol in the mother liquors was also determined by dissolution of product crystals
and HPLC Analysis.
2.3.4. Impurity Analysis Using HPLC
The separation of analytes was achieved using an Agilent Poroshell column operated at 40 ◦C
with an isocratic elution of 1 mL/min, the mobile phase composition was 80% water and 20%
methanol. The detection wavelength was 243 nm, which represents the maximum absorbance for both
paracetamol and metacetamol [66] while still remaining close to the lambda max for acetanilide at
242 nm [67]. The material corresponding to each peak in the chromatogram was identified using mass
spectroscopy. The analytical sample used to determine the purity of the product crystals was prepared
by weighing 14 mg of dry product crystals into a 100 mL volumetric flask and dissolving them in a
5% methanol/95% water mixture to prepare a solution with a concentration which was within the
concentration range used to calibrate the instrument. Mother liquors were similarly diluted by mass to
ensure appropriate composition for assay.
3. Results
3.1. Solubility
The solubility curves of paracetmol, metacetamol and acetanilide in 3-methyl-1-butanol prepared
using the isothermal equilibration and gravimetric analysis and polythermal dissolution temperature
detection method are shown in Figure 3. These data are summarised in Table 1. Full details of
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the gravimetric studies and dissolution temperature detection are given in Section S1 within the
ESI† materials.
The solubility of paracetamol, metacetamol and acetanilide increase with increasing temperature.
Paracetamol is the least soluble in 3-methyl-1-butanol and acetanilide is the most soluble and exhibits
the strongest dependency on temperature (Figure 3). Examining the data presented in Figure 3,
there was a discrepancy in solubility of metacetamol obtained by isothermal equilibration followed by
gravimetric analysis and by observing the dissolution temperature during heating using the Technobis
Crystalline. Determining the dissolution temperature using the Crystalline involves identifying a
clear point at which dissolution is presumed to have occurred. The clear point was determined using
both transmissivity measurement and examining images from the crystalline camera. The dissolution
kinetics depend on the size and shape of the crystals dissolving and their ability to impede the passage
of light (transmissivity) or to be clearly resolved in an image (camera based measurement). Although
the measurement was performed at a modest heating rate of 0.1 ◦C/min, the possibility of overshooting
the dissolution temperature remained. Metacetmol has a very thin needle-like crystal morphology;
the crystals appear to persist some while after they could have dissolved in an isothermal experiment.
As a result complete dissolution is detected at slightly higher temperature than seen in the gravimetric
method. Interestingly, there is no similar discrepancy in the data collected using the two methods
for acetanilide, this is believed to be due to the higher solubility of acetanilide and the more rapid
dissolution which may be linked to the thin plate-like crystal habit.
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Figure 3. Solubility of paracetamol, metacetamol and acetanilide in 3-methyl-1-butanol obtained by
isothermal equilibration followed by gravimetric analysis and by observing the dissolution temperature
during heating using the Technobis Crystalline.
Table 1. Molecular weights, melting points, enthalpy of fusion and measured solubilities of
paracetamol, metacetamol and acetanilide determined using the gravimetric method.
Compounds Molecular Weight (g/mol) Melting Point (K) ∆Hfusion (kJ mol
-1)
Measured Solubility in
3-methyl-1-butanol (mg/g)
25 ◦C 40 ◦C 55 ◦C
Paracetamol 151.16 443.6 [68]; 442.9 [69] 27.1 [68]; 30.72 [69] 54.8 74.3 124.3
Metacetamol 151.16 420 [70,71] 26.0 [71]; 28.8 [70] 81.4 116.7 162.6
Acetanilide 135.17 387.5 [69] 20.30 [69] 162.8 241.8 -
The solubility of a crystalline organic material typically depends on the lattice structure
(polymorph), melting point, molecular weight and solvent choice. The measured solubility of
paracetamol and metacetamol are relatively similar in comparison with acetanilide, this is consistent
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with their relationship as positional isomers containing the same functional groups. The paracetamol
crystal structure is dominated by hydrogen-bondedmolecular chains packed in a ‘herring bone’ pattern.
Similarly, metacetamol crystals are bound together by a network of hydrogen bonding interactions.
Acetanilide however has no hydroxyl group in the para-position so lacks a proton donor. In addition,
the melting point and the enthalpy of fusion decrease in the order Paracetamol > Metacetamol >
Acetanilide (see Table 1). For acetanilide the crystal structure is such that molecules are bound by
weaker forces than in paracetamol due to lack of the hydroxyl group reducing the opportunity to form
a hydrogen bonding network. Acetanilide has a substantially lower heat of fusion and a lower melting
point than paracetamol and metacetamol. The relative solubility is presumed to affect the impurity
segregation of the final crystalline product.
The data presented in Figure 4 indicate that the presence of 1–4% of the selected impurities
does not significantly affect the solubility of paracetamol. At 25 ◦C and 40 ◦C, it was shown that the
solubility is similar or increases slightly with the presence of the selected impurities. At 55 ◦C, the data
shows increased scatter and the trend is less pronounced. It can be concluded that the effect of 1–4%
metacetamol/acetanilide on the solubility of paracetamol is modest.
Figure 4. Solubility of paracetamol in 3-methyl-1-butanol with the presence of impurities (metacetamol
and acetanilide) obtained by equilibration and gravimetric assay.
3.2. Ultrasonic Intensity Measurements
The ultrasound intensity measurements reveal that the local ultrasonic field is highly chaotic and
intensities range from 0.12 to 0.25 mW/cm2 at 50% ultrasonic power and from 0.9 to 1.68 mW/cm2 at
100% power (see Table 2). It is clear from this data that the % ultrasound power is not a linear descriptor.
Crystallisation experiments were conducted at positions 1 and 2 and the ultrasound intensity applied
during these experiments can be characterised as; zero (0 mW/cm2) low, 50% ultrasound power
(0.19 ± 0.06 mW/cm2) and high, 100% ultrasound power (1.45 ± 0.21 mW/cm2).
Table 2. The ultrasonic intensity was measured at four positions within the ultrasonic bath.
Positions on the Stirrer plate at the Bottom of the Ultrasonic Bath
Ultrasonic Intensity (mW/cm2)
50% Ultrasonic Power 100% Ultrasonic Power
1 0.13 ± 0.02 1.25 ± 0.13
2 0.25 ± 0.03 1.68 ± 0.25
3 0.24 ± 0.02 1.32 ± 0.09
4 0.12 ± 0.04 0.9 ± 0.07
Average values 0.19 ± 0.07 1.29 ± 0.32
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3.3. Sonocrystallisation
The data comprise 11 suspension crystallisation experiments designed using the Design of
Experiments software MODDE. (Umetrics Modde, Version 11, MKS Instruments, Umea, Sweden)
to facilitate multivariate analysis. A full factorial (2 level) method was used to create a data set
that was then analyzed using multiple linear regression (MLR) methods to measure effects of the
three independent variables on the experimental responses. The parameters investigated were;
the concentrations of the two impurities where the parameter range was selected as 0–2 mol% and
ultrasonic power where the parameter range was 0% to 100% power settings on the ultrasonic bath.
When the ultrasonic power was measured the center point (50% ultrasound power) the intensity was
found to be 0.19± 0.06mW/cm2 and at 100% ultrasound power the intensity was 1.45 ± 0.21 mW/cm2.
The responses analyzed were nucleation temperature, particle size, filtration rate, product yield and
the percentage of impurities in the product crystals.
The effect of the percentage of impurities present in solution at the start of crystallisation and
ultrasonic power on; nucleation temperature, crystal size distribution, filtration rate and process yield
at a defined crystallisation end point are summarised in Table 3.
Table 3. Summary of crystallisation temperature, crystal size distribution, filtration time (for 50 mL
suspension solution), filtration rate, cake resistance and process yield as a function of the percentage of
impurities and ultrasonic power.
Experiments Tcrys (
◦C)
PSDMean Chord
Length (µm)
Filtration
Time (s)
Filtration
Rate (m3/s)
Cake Resistance
(m/kg)
Yield
Pure paracetamol
(100% power US) 41.3 47–55 209 1.90 × 10
−7 7.03 × 1011 57.7%
Pure paracetamol
(no US) 36.0 85–100 95 4.29 ×1 0
−7 2.62 × 109 54.3%
2 mol% Metacetamol
(100% power US) 36.4 47 361 1.07 × 10
−7 1.52 × 1010 45.5%
2 mol% Metacetamol
(no US)
After maintaining
at 15 ◦C for
approx. 1.5 h
100–109 45 1.06 × 10−7 9.02 × 108 39.1%
2 mol% Acetanilide
(US 100%P) 43 40 561 7.32 × 10
−7 1.88 × 1010 56.2%
2 mol% Acetanilide
(no US) 15.5
◦C 105 54 7.01 × 10−7 1.02 × 109 55.3%
2 mol% Metacetamol &
Acetanilide
(US 100% power)
34.4 37.3 346 1.19 × 10−7 1.51 × 1010 42.2%
2 mol% Metacetamol &
Acetanilide (no US)
After maintaining
at 15 ◦C for
approx. 2.5 h
87–90 48 9.61 × 10−7 1.14 × 109 32.0%
1 mol% Metacetamol &
1 mol% Acetanilide
(50% US power)
44 87 61 7.19 × 10−7 1.38 × 109 40.6%
3.3.1. Crystallisation Temperature
The nucleation temperature measured with and without the use of ultrasound for crystallisation
of paracetamol in the presence of metacetamol and/or acetanilide is shown in Table 3. Even though
nucleation is a stochastic process and some scatter may be anticipated among the measured data
the experimental results clearly show that ultrasound has a significant effect on the nucleation
process. For example, in the case of paracetamol crystallisation in the presence of 2% metacetamol,
the ultrasound treated sample started to nucleate at around 36 ◦C, and was in the final stages of
crystallisation by the time the suspension had been cooled to 15 ◦C. By contrast the sample not treated
with ultrasound only started to nucleate after holding at 15 ◦C for approximately 1.5 h. This is believed
to be due to the slow nucleation and crystal growth kinetics in the presence of impurities. Ultrasound
can promote nucleation and generate substantial numbers of secondary nuclei from existing parent
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crystals in the reactors. This is consistent with previous work [19,26,27,47] undertaken at different
frequencies by different researchers. Although different frequencies have been employed and the
intensity of cavitation is likely to have varied significantly between studies the research consistently
shows that nucleation may be triggered at lower supersaturation levels and the nucleation rate may
be increased with the use of ultrasound. There are two classical mechanisms of secondary nucleation
(i) due to collisions between crystals and crystals colliding with the wall of the crystallizer or the
agitator and (ii) removal of an ordered surface layer from the parent crystals due to fluid shear stresses.
It is logical to anticipate that these phenomenon are amplified by application ultrasound. Cavitation
occurring on, or near, crystal surfaces causes intense shear stresses which can lead to secondary
nucleation [18,20,72,73]. It is suggested that ultrasound energy overcomes the kinetic barriers to
nucleation by reducing the activation energy, and hence reducing the induction time. Ultrasound
significantly decreased the metastable zone width, where the results indicate that the apparent order
of primary nucleation is reduced and thus increases the solid precipitation rate [26]. During transient
cavitation bubbles are formed and destroyed, this phenomenon creates localised supersaturation,
which causes nucleation to occur. Similarly, the sonocrystallisation of mono and disaccharides from
aqueous solution showed similar trends in a cooling crystallisation experiment, where ultrasound
was applied, samples crystallised at higher temperature than in absence of ultrasound [46]. However,
in another case, for amino acids the induction period increased with increasing ultrasonic irradiation
energy up to a certain degree and subsequently decreased [74].
Crystal yield is calculated as the percentage of the mass of recovered product crystals following
filtration washing and drying compared to the mass of input material. This contains an implicit
assumption that there is no significant dissolution of crystals during washing which is justified based
on the very low solubility of paracetamol in n-heptane, and the amount of paracetamol or impurities
deposited from evaporation of retained wash liquor is negligible again due to the very low solubility.
There are however product losses associated with material handling and with residues left on vessel
walls and agitators. In addition some product losses are due to filtration and washing taking place at
ambient temperature for reasons of practicality even though the crystallisation was halted at 15 ◦C.
The typical estimated loss by these mechanisms is around 5%. The data in Table 2 indicate that
intervention with ultrasound improves the product yield. In this series of experiments the yield is
limited to 65% by the solubility at the isolation temperature based on the solubility in a pure system.
The effect of impurities on the solubility at the isolation point has been shown to be negligible at the
impurity concentrations investigated. For this reason, it is appropriate to use the same reference point
to assess the yield in the experiments where impurities were present as it presents the yield with
respect to a consistent baseline. The average yield for ultrasound treated samples is 50.7%, whereas
for non-ultrasound treated samples the average yield is 45.2% (see Figure 5). This reduction in yield
may be explained by considering the impact of ultrasound on several aspects of the crystallisation
process. The non-ultrasound treated samples nucleate later in the process and the total number of
nuclei is lower resulting in less surface area for growth and hence less opportunity for the solution to
desupersaturate completely within the timeframe of the experiment. During crystal growth, enhanced
local mass transfer arising from ultrasound irradiation increases the rate of mixing in the boundary
layer, potentially accelerating the crystal growth process.
While it is well established that applying ultrasound to supersaturated solutions can initiate
nucleation, the mechanism by which this takes place is not known. The bubble collapse associated with
transient cavitation is reported to produce short lived and highly localised extremes of temperature and
pressure which may contribute to a system overcoming energy barriers for nucleation. The passage of a
sound wave is facilitated by molecular motion which may potentially promote cluster collisions which
favours nucleation; however it may also serve to disrupt clusters. Cavitation events tend to be focused
on discontinuities in the liquid phase and once crystals have formed these provide a readily available
source of discontinuities which may act as cavitation centres and so contribute to the formation of
new secondary nuclei. Prior to nucleation foreign particles such as dust are the principal source
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of discontinuities which can act as sites for cavitation. Applying ultrasound during crystal growth
speeds up the growth kinetics of crystals; several mechanisms can be proposed. Ultrasound enhances
mixing [22,28,37,45,75] both through acoustic streaming and through the formation and subsequent
collapse of cavitation bubbles which tend to be focused on existing crystals. These processes will
enhance mass transfer within the boundary layer adjacent to the crystal. A further potential mechanism
is the detachment of impurity molecules from the surface layer of the crystal eliminating the tendency
for the impurities to block crystal growth. A consequence of the more complete de-supersaturation
associated with insonation is that less solute remains in solution in the mother liquor. In combination,
these processes triggered by insonation result in an increase of yield for the crystallisation process.
Similarly, studies of crystallisation of lactose [42,55] showed the sonicated samples had higher yields
than non-sonicated samples. This confirms that ultrasound can be applied to deliver a faster and more
efficient crystallisation process.
 
Figure 5. Yield of crystallisation with and without ultrasound in comparison with the yield limited
by solubility to 65%, showing yield for the crystallisation process that approaches the equilibrium
yield more closely with the use of ultrasound and that the presence of impurities impedes the
desupersaturation process.
3.3.2. Crystal Size Distribution
The data presented in Figure 6 show that paracetamol crystallized in the presence of either of the
impurities, metacetamol, acetanilide or both in combination has a narrower particle size distribution
and a substantially larger number of smaller crystals when obtained with the use of ultrasound.
For example, for the case of 2% of the impurity metacetamol, the sample treated with ultrasound at
100% power (1.45 ± 0.21 mW/cm2) has a mean square weight (chord length) of 49 µm and many
more particles than the corresponding sample which was not exposed to ultrasound which has a
mean square weight of 109 µm. It is believed that application of ultrasound generates a substantial
number of secondary nuclei which leads to a smaller product crystal size. Considering Figure 6a,
it is noticeable that particle size distribution of the DOE centre point sample containing 1% of each of
the impurities and subjected to the low (50% ultrasound power) is closer to the non insonated pure
sample than the intensely insonated pure sample. This is consistent with both the impact of impurities
inhibiting nucleation and growth combined with the low ultrasound intensity at the 50% power level
(0.19 ± 0.06 mW/cm2) compared with the high, 100% ultrasound power (1.45 ± 0.21 mW/cm2).
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Figure 6. Particle size distribution of paracetamol crystals measured in situ at the end of crystallisation
in the presence of impurities using an FBRM with and without the use of ultrasound (a) Pure
paracetamol and 1% Metacetamol and 1% Acetanilide; (b) 2% acetanilide; (c) 2% Metacetamol; (d) both
2% Acetanilide and 2% Metacetamol.
Ultrasound has been reported to cause crystal breakage [20,37,39,76–78]. The breakage rate
triggered by stable cavitation is reported to be independent of the applied power for paracetamol
crystals with a median size (volume based distribution) of 75 µm and that a particle size threshold
of ca. 35 µm exists. The particle size could not be reduced below this size regardless of the applied
power or frequency. For transient cavitation, in contrast, higher powers lead to considerably smaller
particles, with no threshold size within the investigated power range [79]. The effect is pronounced
with a reduction in particle size of almost 70% compared to silent conditions is attained by using
ultrasound [80]. It has been reported that low frequencies (≤166 kHz) show a significant decrease in
resultant particle size while high frequencies (>166 kHz) do not result in particle breakage [79].
The PSD in this studywas compared to previous studies on paracetamol by Bhangu S. K. et al. [81]
and with other organic materials which have been subject to ultrasonic irradiation (see Section S2
Supplementary data). The PSDs measured in situ at the end of crystallisation and prior to isolation
were found to be consistent with literature data for the case of ultrasound assisted crystallisation of
paracetamol [81].
3.3.3. Crystal Habit
Crystal habit has significant influence on the filtration washing and drying processes. It also plays
a critical role in defining key physical properties of products including flow-ability and compressibility
which are important in subsequent formulation processes. Figures 7 and 8 provide representative
images of crystals of the isolated dry product. The ultrasound treated samples appear consistently
smaller than the untreated product crystals, which is consistent with the measured PSD. The habit
of crystals of paracetamol produced in this study is typically diamond shaped platelets regardless
of whether they were produced with or without the use of ultrasound. The non-ultrasound treated
samples showed the more consistent habit, which is similar to the commonly observed external
morphology of the monoclinic form of paracetamol crystallised from pure IPA and with 1–2 mol%
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metacetamol [5]. By contrast the ultrasound treated samples, contained particles which were more
difficult to disperse; this is likely to be due to the much smaller crystals being more prone to
agglomeration during drying. The crystal facets were also found to be damaged potentially due to
increased particle breakage when subject to ultrasound particularly at the highest intensity. The images
in Figure 8 for crystallisations taking place without ultrasonic intervention suggest that the crystals
grown in the presence of impurities are better faceted than those grown from pure solution, this is
consistent with the impact of impurities in slowing growth and yielding more visually perfect crystals.
The crystal size is smaller with an impurity loading of 2% of both impurities compared to the case of
1% of both impurities. When ultrasound is applied the crystal size is more uniform but much smaller
than in comparison to the experiments with no ultrasound. Lower ultrasound power level (50%)
does not reduce crystal size as significantly relative to the experiments at 100% ultrasonic power level.
This is consistent with the ultrasonic intensity data reported in Section 3.2.
 
Figure 7. Optical microscopy images of recrystallized paracetamol crystal habit (from the left to the
right) for the case of no added impurities with no US, with addition of 2% acetanilide with no US,
with addition of 2% metacetamol with no US, with addition of 2% metacetamol and 2% acetanilide
with no US, with addition of 1% metacetamol and 1% acetanilide with no US, with addition of 1%
metacetamol and 1% acetanilide with 50% US power. Scale bar: 100 µm.
 
Figure 8. Optical microscopy images of recrystallized paracetamol crystal habit (from the left to the
right) for the case of paracetamol with addition of 2% mol acetanilide with no US and 100% US power,
paracetamol with addition of 2% mol metacetamol with no US and 100% US power, paracetamol with
addition of 2% mol metacetamol and 2% mol acetanilide with no US and 100% US power. Scale bar:
100 µm.
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3.3.4. Particle Isolation by Filtration
The paracetamol crystals were separated from their mother liquor after crystallisation by
filtration. The crystallisation was scaled such that there was sufficient slurry to conduct three
replicate experiments for each filtration. The variance in filtration rate provides an indication of the
challenge associated with obtaining a representative suspension sample from a larger scale operation.
The measured values are averaged across the replicate measurements to provide a representative
measure of the filtration performance. The filtration data collected included filtration rate, filtration
duration and filter cake resistance which are shown in Table 3 and Figure 9.
 
 
Figure 9. (a) Volume of filtrate collected versus time showing the filtration duration and filtration rate
of ultrasound treated and non-ultrasound treated samples; (b) Plot of time/volume of filtrate collected
(t/V) versus volume of filtrate (V) showing the ultrasound treated samples filter much more slowly
and have correspondingly higher cake resistances (reported in Table 3) than the un-treated samples.
Comparing the ultrasound-treated and non-ultrasound treated samples, in the case of paracetamol
crystallized from 2% metacetamol, the ultrasound treated sample had a filtration duration of 361 s
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which is much longer than the 45 s taken by the non-ultrasound treated sample. This is consistent
with the much smaller particle size distribution of the ultrasound treated sample this is supported
both by FBRM and optical microscopy. The small crystals of the insonated sample pack to form a
cake which contains relatively narrow pores between particles. This cake structure impedes the flow
of filtrate through the cake compared with a cake formed of larger particles with correspondingly
larger inter-particle pores. As a consequence, the filtration rates determined for the ultrasound
treated samples are much lower than the non-ultrasound treated samples. In terms of cake resistance,
the ultrasound treated samples exhibit a higher resistance compared with the non-ultrasound treated
samples. For the non-ultrasound treated samples we can see that the gradient is around three times
greater than the ultrasound treated samples (see Figure 9). As a result, the sample exhibits a higher
cake resistance and thus increasing the filtration time. As particle size decreases, cake resistance
increases, and cake filtration can result in excessively long filtration times. A second reason for the
increase in filtration duration with ultrasound is that the yields are higher and hence the mass of
material to be filtered is greater. For example in the case of the pure material and the sample with 2%
acetanilide the yield is 54% and 55% respectively, whereas the samples containing 2% metacetamol and
the combination of 2% metacetamol and 2% acetanilide have lower yields of 39% and 32% respectively.
The lower yields are believed to be due to the impurities poisoning crystal growth.
The viscosity of the mother liquors was measured as a necessary parameter to apply Darcy’s
equation. The viscosity of the mother liquors was determined using a GV500 viscometer (Hydramotion
Ltd., Malton, York, UK). A consistent value of 0.0057 Pa·s was recorded across all samples. The cake
resistance was found to be in the range 1.5 × 1010 to 7.0 × 1011 kg/m for paracetamol with 2% of
each impurity and the combination of 2% of both impurities for ultrasound treated samples and in
the range of 9.0 × 108 to 2.6 × 109 kg/m for samples prepared in the absence of ultrasound and 50%
power ultrasound treated samples. Insonication at the lower ultrasound power level (50%) has little
effect on the crystal size. For the 50% power ultrasound treated samples this is consistent with the
measured filtration duration and cake resistance.
From a formulation perspective it is often desirable to produce API crystals with a small particle
size to achieve content uniformity in tablets and to enhance bioavailability, typically this is achieved
by dry milling isolated product. The application of ultrasound leads to increased duration of isolation
but this may offset against eliminating the additional processing step of size reduction.
3.3.5. Crystal Purity
One of the important success criteria for a crystallisation process is product purity. Each product
sample was assayed by HPLC and the data is reported in Table 4.
Table 4. Summary of percentage of each compound in crystal product and in mother liquor.
Experiment Conditions Compounds
Percentage of Compounds in
Crystal Product (%)
Percentage of Compounds in
Mother Liquor (%)
With US No US With US No US
Pure Paracetamol
Paracetamol 100 100 100 100
Metacetamol 0 0 0 0
Acetanilide 0 0 0 0
Paracetamol with 2% Acetanilide
Paracetamol 99.62 99.15 94.65 96.02
Acetanilide 0.35 0.85 5.35 3.98
Paracetamol with 2% Metacetamol
Paracetamol 98.47 98.12 96.05 96.43
Metacetamol 1.52 1.88 3.95 3.57
Paracetamol with 2% Metacetamol
and 2% Acetanilide
Paracetamol 98.1 97.98 91.37 91.49
Metacetamol 1.19 1.44 3.91 3.92
Acetanilide 0.55 0.58 4.72 4.59
The results show that the ultrasound treated product crystals contain less impurity than the
non-insonated samples. This was the case for example with the paracetamol product isolated from
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the 2% metacetamol solution where the concentration of the impurity in the product is reduced from
1.88% to 1.52%. Likewise the uptake of acetanilide from the 2% acetanilide crystallisation is reduced
from 0.85% to 0.35%. The impurity analysis of the filtrate shows that more of the impurities remain in
solution in the ultrasound treated samples. This result is more striking when the difference in particle
size between the ultrasound treated and non-treated samples is considered. The ultrasonically treated
products comprise far more smaller particles which have a much greater combined surface area on
which impurities in the mother liquor may be retained and furthermore provide a larger washing
challenge due to the finer pore structure and increased contact area between particles. Also, when the
impurity loading in the crystallisation solution is highest the particle size is reduced to the larger
extent, for example the case of 2% metacetamol and acetanilide.
Several mechanisms for impurity incorporation into crystalline products have been identified:
(i) Surface adhesion/adsorption on the crystal surface; (ii) Bulk phase inclusion of mother liquor e.g.,
through agglomeration; (iii) inclusions of mother liquor within individual crystals and (iv) molecular
substitution at the lattice sites. Potential purification methods for impurities in these different locations
may be proposed. One mechanism by which the improvement in purity of crystals formed with
continuous ultrasonic irradiation that can be proposed is that ultrasound produces very localised but
short lived hot spots within the product crystal suspension. These hot spots are generated during the
collapse of cavitation bubbles. Potentially this could provide sufficient perturbation to remove the
mismatched impurity molecules from the product crystal lattice/surfaces due to the reduced binding
energy associated with the different substrates. Another possible mechanism arises from reports
that ultrasound may lead to a reduction in the formation of particle-particle agglomerates which in
turn reduces the extent of agglomeration and so make the washing process more effective. A further
observation is that, metacetmol appears to be more readily incorporated into the crystal product
when compared to acetanilide. There may be several contributing causes for this segregation of the
impurities (i) acetanilide is more soluble in 3-methyl 1-butanol than metacetamol; (ii) Metacetamol
inhibits both nucleation and crystal growth more than acetanilide leading to reduced particle size
making the filtration and washing process more challenging.
3.3.6. DoE and Multivariate Analysis
Using design of experiments, a multivariate approach, the combined effects of ultrasound power
and impurity content on the crystallisation of paracetamol from 3-methyl 1-butanol were evaluated.
Figure 10 shows both single factor and two factor effects on (a) Nucleation temperature; (b) Particle
size; (c) Acetanilide incorporation; (d) Metacetamol incorporation and (e) Yield. From this it is clear
that ultrasound plays a dominant role in triggering nucleation at higher temperatures (a) and reducing
the mean particle size (b), is has a more modest effect in increasing yield (e) where the dominant effect
is the presence of metacetamol. As expected the principal factor influencing the amount of impurity
in the product is the impurity concentration is the feed solution (c-acetanilide) and (d-metacetamol).
Most two factor effects are relatively modest.
(a) (b)
Figure 10. Cont.
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(c) (d)
(e)
Figure 10. Effect of coefficients (using MLR model) from DoE showing the extent of the effect of
factors on the responds; nucleation temperature (a), PSD (b), acetanilide in product (c), metacetamol in
product (d), and yield (e).
The Figure 11a–e provides further detail of the predicted impact of the experimental factors,
for example Figure 11a,b reveal that the difference in nucleation temperature between the least and
most forcing conditions exceeds 20 ◦C. Comparing Figure 11c,d show that ultrasound is the dominant
variable in modifying particle size. Figure 11e,f show that the presence of acetanilide has little impact
on yield whereas metacetamol has a significant effect, reducing yield by around 25%. Figure 11g,h
show the effect of insonation on isolated product purity, it is readily apparent that ultrasound has a
significant effect in reducing acetanilide incorporation into the product but is less effective in reducing
the level of metacetamol incorporation.
(a) (b)
(c) (d)
Figure 11. Cont.
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(e) (f)
(g) (h)
Figure 11. Response contour plot showing effect of ultrasound power (from 0 to 100% ultrasonic
power), acetanilide and metacetamol impurity (0 to 2% mol) on nucleation temperature (a,b), PSD (c,d),
yield (e,f) and the percentage of impurities in crystal product (g,h).
The combined effects are represented in Figure 12 which allows the relative magnitude of
ultrasound and the two impurities on PSD, yield and nucleation temperature to be assessed.
(a) (b)
Figure 12. Respond surface plot showing the effect of ultrasound intensity, metacetamol (a) and
acetanilide (b) concentration on crystal size, yield and nucleation temperature.
4. Discussion
The nucleation point recorded in the 150 mL flasks for the non-sononucleated samples are in good
agreement with one another; there is some variability which is consistent with the stochastic nature
of nucleation. For pure paracetamol, the sub-cooling required to induce nucleation in the absence
of ultrasound is around 30 ◦C. It has been shown that metacetamol has a more significant effect on
metastable zone width than acetanilide causing increased induction time.
Due to the earlier nucleation point and larger number of nuclei in the sononucleated samples
the available surface area for growth is greater than in the non-sononucleated samples, this has
an impact throughout the subsequent crystallisation and isolation. There is a strong link between
ultrasound effects on nucleation kinetics, product crystal size distribution, filtration rate and product
purity. The principal attribute of the crystals which affects filtration performance is the crystal-size
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distribution. At the maximum (100%) ultrasonic intensity some evidence of crystal damage is
seen in the photomicrographs. In terms of product crystal purity, several mechanisms of impurity
incorporation have been identified; adhesion/adsorption on crystal faces; bulk inclusion of mother
liquor entrapped between particles; inclusions of mother liquor within individual crystals; molecular
substitution within the lattice and incomplete removal of mother liquors during washing. In this bulk
crystallisation investigation evidence has been gathered which suggests that ultrasonic intervention
does lead to higher crystal purity. However it has not been possible to attribute specific quantities of
the overall impurity loading between these different mechanisms.
The proposed mechanism for the effects seen in the present work involves (i) Crystal growth is
the selective process through which growing crystal recognizes the host and rejects impurities. Since
the impurity molecules differ from the host molecules, they do not fit the growth site as easily as the
host (solute) molecules. The greater the structural similarity between impurity and host molecules,
the more readily the impurity molecules incorporate into the crystal lattice. During the growth process
when impurities arrive at the crystal surface, they diffuse across the surface until they access a position
with a sufficiently strong binding interaction that they attach to, and become incorporated into the
lattice. If ultrasound is applied at an appropriate intensity, frequency and duration, it is proposed
that the molecular motion and fluctuation in pressure and temperature associated with the passage
of the ultrasound wave may replace the molecules in the boundary layer surrounding the crystal
with molecules from the bulk solution. At ultrasound intensities above the cavitation threshold it is
proposed that the shockwave and associated local heating arising from the collapse of a cavitation
bubble disturbs the local equilibrium at the liquid/solid interface and may selectively remove impurity
molecules from the crystal surface due to weaker binding energy associated with the imperfect fit
to the lattice. (ii) In addition, when sonocrystallisation is employed, nucleation is initiated at lower
supersaturations than would be the case without ultrasonic intervention. As a consequence, more of
the crystal growth takes place at lower supersaturation levels than in a spontaneously nucleated
crystallisation, during growth at lower supersaturation the crystal faces tend to be smoother, and the
rate of growth lower, providing increased opportunity for impurity molecule removal from growth
sites prior them being overgrown and hence built into the bulk of the crystal resulting in less impurity
becoming incorporated into the final product. (iii) Ultrasound increased molecular motion adjacent to
the growing crystal improving transport to and from the crystal faces. Highly localised perturbations
caused by cavitation events lead to momentary local temperature fluctuations. When these occur close
to strained regions of the lattice where impurities are attached they favour release of the impurity
molecules. While these hypotheses are plausible the experimental evidence gathered here does not
provide significant further mechanistic clarification.
5. Conclusions
The effect of sono-crystallisation on paracetamol product purity has been demonstrated for two
structurally similar impurities. The classic benefits reported for sono-crystallisation; acceleration of
nucleation, modification of crystal size distribution, and enhancement of yield have been confirmed.
The work has added another dimension, that ultrasound intervention during crystallisation in the
presence of impurities can enhance product crystal purity. However, the underlying mechanisms of
this effect are not yet well understood.
These findings provide convincing evidence for the potential application of ultrasound to other
organic systems to enhance purification. Through this work, an insight into the possibilities of
enhancing purity of pharmaceutical products by sonocrystallisation has been demonstrated.
Supplementary Materials: The following are available online at www.mdpi.com/2073-4352/7/10/294/s1,
Section S1: Data related to solubility of paracetamol, metacetamol and acetanilide in 3-methyl-1-butanol, Section
S2: Comparison of the mean PSD of paracetamol nucleated and grown in the presence of structurally similar
impurities (this work) with the PSD of some organic materials obtained from sonocrystallisation from literature.
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